In a treatment-naïve ovarian tumor-bearing mouse model, upfront combination therapy effectively promoted an anti-tumor microenvironment, as evidenced by an increase in CD86+CD206- macrophage cells and a concomitant decrease in CD86-CD206+ macrophage cells. The gene discussed is MRC1; the disease is ovarian neoplasm.